PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC has commenced an investigation of IVERIC bio, Inc. (“IVERIC” or the “Company”) (Nasdaq: ISEE), formerly known as Ophthotech Corp., on behalf of the Company’s stockholders.
IVERIC stockholders who purchased shares of the Company’s stock before December 12, 2016 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740 to discuss this investigation and their legal rights and options. Additional information about this investigation may also be found at http://kaskelalaw.com/case/iveric-bio-inc/.
In 2017, a shareholder securities fraud complaint was filed against the Company in federal court on behalf of certain purchasers of IVERIC’s common stock. Among other things, the shareholder complaint alleges that IVERIC violated the federal securities laws by making a series of materially false and misleading statements to investors regarding the parameters and results of clinical studies for Fovista.
Kaskela Law LLC is investigating whether IVERIC’s executive officers and/or directors breached their fiduciary duties to the Company and its stockholders in connection with the above alleged misconduct.
Kaskela Law LLC prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.